Analysis of real-world data demonstrating the efficacy of current management of polycythaemia vera in attaining and maintaining therapeutic haematocrit

Frances D. Buckley; Claire Arnold; Dawn Brass; Mark Catherwood; Mary Frances McMullin

doi:10.1007/s11845-023-03510-7

Analysis of real-world data demonstrating the efficacy of current management of polycythaemia vera in attaining and maintaining therapeutic haematocrit

Frances D. Buckley, Claire Arnold, Dawn Brass, Mark Catherwood, Mary Frances McMullin^*

^*Corresponding author for this work

School of Medicine, Dentistry and Biomedical Sciences

Research output: Contribution to journal › Article › peer-review

36 Downloads (Pure)

Abstract

Background
Polycythaemia vera (PV) is a Philadelphia-negative myeloproliferative neoplasm, typically driven by acquired JAK2 mutation and characterised by elevated red cell mass and increased risk of thrombotic events. Patients are managed with phlebotomy to maintain haematocrit (Hct) < 0.45, and patients stratified as ‘high risk’ for thrombosis are additionally treated with cytoreductive agents to attain this target.

Study
This analysis of newly diagnosed JAK2 mutant PV patients (n = 50) over 2 years aimed to determine how effectively patients attained and maintained target Hct according to recommended practice.

Conclusions
We found that patients spent the majority of time in target Hct range. Findings are supportive of current management guidelines.

Original language	English
Pages (from-to)	833-836
Number of pages	4
Journal	Irish Journal of Medical Science
Volume	193
Issue number	2
Early online date	08 Sept 2023
DOIs	https://doi.org/10.1007/s11845-023-03510-7
Publication status	Published - Apr 2024

Keywords

Haematology
Myeloproliferative neoplasms
Polycythaemia

Access to Document

10.1007/s11845-023-03510-7Licence: CC BY

Analysis of real-world data demonstrating the efficacy of current management of polycythaemia vera in attaining and maintaining therapeutic haematocrit
Copyright 2023 The Authors. This is an open access article published under a Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium, provided the author and source are cited.
Final published version, 555 KBLicence: CC BY

Cite this

@article{6683532ebffb4398aa7b6d98f7c1aa5c,

title = "Analysis of real-world data demonstrating the efficacy of current management of polycythaemia vera in attaining and maintaining therapeutic haematocrit",

abstract = "BackgroundPolycythaemia vera (PV) is a Philadelphia-negative myeloproliferative neoplasm, typically driven by acquired JAK2 mutation and characterised by elevated red cell mass and increased risk of thrombotic events. Patients are managed with phlebotomy to maintain haematocrit (Hct) < 0.45, and patients stratified as {\textquoteleft}high risk{\textquoteright} for thrombosis are additionally treated with cytoreductive agents to attain this target.StudyThis analysis of newly diagnosed JAK2 mutant PV patients (n = 50) over 2 years aimed to determine how effectively patients attained and maintained target Hct according to recommended practice.ConclusionsWe found that patients spent the majority of time in target Hct range. Findings are supportive of current management guidelines.",

keywords = "Haematology, Myeloproliferative neoplasms, Polycythaemia",

author = "Buckley, {Frances D.} and Claire Arnold and Dawn Brass and Mark Catherwood and McMullin, {Mary Frances}",

year = "2024",

month = apr,

doi = "10.1007/s11845-023-03510-7",

language = "English",

volume = "193",

pages = "833--836",

journal = "Irish Journal of Medical Science",

issn = "0021-1265",

publisher = "Springer-Verlag London Ltd",

number = "2",

}

TY - JOUR

T1 - Analysis of real-world data demonstrating the efficacy of current management of polycythaemia vera in attaining and maintaining therapeutic haematocrit

AU - Buckley, Frances D.

AU - Arnold, Claire

AU - Brass, Dawn

AU - Catherwood, Mark

AU - McMullin, Mary Frances

PY - 2024/4

Y1 - 2024/4

N2 - BackgroundPolycythaemia vera (PV) is a Philadelphia-negative myeloproliferative neoplasm, typically driven by acquired JAK2 mutation and characterised by elevated red cell mass and increased risk of thrombotic events. Patients are managed with phlebotomy to maintain haematocrit (Hct) < 0.45, and patients stratified as ‘high risk’ for thrombosis are additionally treated with cytoreductive agents to attain this target.StudyThis analysis of newly diagnosed JAK2 mutant PV patients (n = 50) over 2 years aimed to determine how effectively patients attained and maintained target Hct according to recommended practice.ConclusionsWe found that patients spent the majority of time in target Hct range. Findings are supportive of current management guidelines.

AB - BackgroundPolycythaemia vera (PV) is a Philadelphia-negative myeloproliferative neoplasm, typically driven by acquired JAK2 mutation and characterised by elevated red cell mass and increased risk of thrombotic events. Patients are managed with phlebotomy to maintain haematocrit (Hct) < 0.45, and patients stratified as ‘high risk’ for thrombosis are additionally treated with cytoreductive agents to attain this target.StudyThis analysis of newly diagnosed JAK2 mutant PV patients (n = 50) over 2 years aimed to determine how effectively patients attained and maintained target Hct according to recommended practice.ConclusionsWe found that patients spent the majority of time in target Hct range. Findings are supportive of current management guidelines.

KW - Haematology

KW - Myeloproliferative neoplasms

KW - Polycythaemia

U2 - 10.1007/s11845-023-03510-7

DO - 10.1007/s11845-023-03510-7

M3 - Article

C2 - 37682452

SN - 0021-1265

VL - 193

SP - 833

EP - 836

JO - Irish Journal of Medical Science

JF - Irish Journal of Medical Science

IS - 2

ER -

Analysis of real-world data demonstrating the efficacy of current management of polycythaemia vera in attaining and maintaining therapeutic haematocrit

Abstract

Keywords

Access to Document

Fingerprint

Cite this